Symbols

IONS

Ionis Pharmaceuticals·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 4

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Gap Down

Significant Net Income Decline

RSI Oversold

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About IONS

Ionis Pharmaceuticals, Inc.

The leader in RNA-targeted therapy and pioneering new markets and changing standards of care with its novel antisense technology

Industry

Pharmaceutical

Established Date

Listing Date

05/17/1991

Exchange

NASDAQ Stock Exchange

Full-time Employees

1,402

Fiscal Year Ends

12-31

Website

www.ionis.com

Security Type

Common stock

Office address

2855 Gazelle Court, Carlsbad, CA 92010

Business

Introduction

Ionis Pharmaceuticals, Inc. was incorporated in California in 1989 and changed its state of incorporation to Delaware in January 1991. The company has spent three decades developing RNA-targeted drugs and has grown into a fully integrated commercial-stage biotechnology company with seven listed drugs and a strong pipeline across neurology, cardiometabolic diseases and other high-demand areas for patients. It continues to advance next-generation RNA targeting technologies through independent and collaborative development to deliver innovative therapies to patients with serious diseases.

Company Financials

EPS

IONS has released its 2025 Q4 earnings. EPS was reported at -1.41, versus the expected -1.33, missing expectations. The chart below visualizes how IONS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

IONS has released its 2025 Q4 earnings report, with revenue of 203.00M, reflecting a YoY change of -10.57%, and net profit of -229.00M, showing a YoY change of -120.19%. The Sankey diagram below clearly presents IONS's revenue sources and cost distribution.